Top 10 most anticipated drug launches of 2026 (Fierce Pharma)

#1

The pharmaceutical industry is preparing for a record-breaking year in 2026, with the top 10 most anticipated drug launches projected to generate $45.9 billion in annual sales by 2032. This represents a significant increase over 2025’s projections, driven primarily by a massive surge in the metabolic space.

The Metabolic Leaders

The list is dominated by two highly anticipated obesity and Type 2 diabetes treatments that account for over 60% of the total projected value:

  1. CagriSema (Novo Nordisk): A fixed-dose combination of semaglutide and cagrilintide. With estimated 2032 sales of $17.2 billion, it is the most valuable candidate on the list, aiming for superior weight loss efficacy over current GLP-1 monotherapies.
  2. Orforglipron (Eli Lilly): An oral, small-molecule GLP-1 receptor agonist. Projected at $11.8 billion, its oral delivery and easier scalability make it a critical contender for global markets and needle-phobic patients.

Oncology and Rare Disease Breakthroughs

The remaining candidates address significant unmet needs in oncology, immunology, and neurology:

  • Anito-cel (Gilead/Arcellx): A CAR-T therapy for multiple myeloma, projected to reach $2.5 billion. It aims to compete with J&J’s Carvykti by offering potentially superior survival data and streamlined manufacturing.
  • Brepocitinib (Roivant): A TYK2/JAK1 inhibitor for dermatomyositis, with an estimated $2.3 billion in sales.
  • Icotrokinra (J&J): An oral IL-23 inhibitor for psoriasis, valued at $2.2 billion.
  • Gedatolisib (Celcuity): A pan-PI3K/mTOR inhibitor for breast cancer ($2.1 billion).

Specialized and Cardiovascular Markets

Rounding out the list are assets targeting large patient populations and specific neurological conditions:

  • Ulixacaltamide (Praxis): A treatment for essential tremor ($2.1 billion), which recently received FDA Breakthrough Therapy designation.
  • Baxdrostat (AstraZeneca): An aldosterone synthase inhibitor for hypertension, projected at $2 billion.
  • Camizestrant (AstraZeneca): A next-generation SERD for ER-positive breast cancer ($1.9 billion).
  • Atacicept (Vertex): A dual BAFF/APRIL inhibitor for IgA nephropathy ($1.8 billion).

The 2026 class is characterized by “mega-blockbusters” that could redefine treatment paradigms in metabolic health and oncology, provided they clear regulatory hurdles.

Source Article: https://www.fiercepharma.com/marketing/top-10-most-anticipated-drug-launches-2026

Drug Target Analysis & Longevity Evaluation

The following analysis evaluates the top 2026 drug launches through a geroscience lens. While these agents are developed for pathology, several target pathways critical to aging (mTOR, Inflammation, Metabolic dysregulation).

Legend:

  • Target/MOA: The specific biological mechanism.
  • Longevity Potential: Viability for off-label preventative use in healthy adults.
  • Evidence Grading: Level A (Meta-analysis), Level B (RCT), Level C (Observational), Level D (Pre-clinical/Mechanistic).

1. CagriSema (Novo Nordisk)

  • Target/MOA: Dual Agonist: Semaglutide (GLP-1 receptor agonist) + Cagrilintide (Amylin/Calcitonin receptor agonist).
  • Mechanism: Synergistic activation of GLP-1 and amylin pathways to induce profound weight loss (>20%) and glycemic control. Cagrilintide targets the area postrema to enhance satiety independent of the GLP-1 pathway.
  • Longevity Potential: High.
    • Rationale: Obesity and insulin resistance are primary accelerators of aging. By achieving weight loss comparable to bariatric surgery, this combination likely confers significant healthspan benefits (reduced cardiovascular risk, neuroprotection). The addition of amylin (which delays gastric emptying) may blunt post-prandial glucose spikes more effectively than GLP-1 alone.
    • Caveat: Rapid muscle loss (sarcopenia) is a known risk of potent weight loss drugs; maintaining protein intake/resistance training is non-negotiable for longevity users.
  • Evidence:

2. Orforglipron (Eli Lilly)

  • Target/MOA: Non-peptide GLP-1 Receptor Agonist (Small Molecule).
  • Mechanism: An oral, once-daily small molecule that activates the GLP-1 receptor. Unlike peptide-based semaglutide (which requires specific absorption enhancers), this is a standard chemical drug.
  • Longevity Potential: High.
    • Rationale: Democratizes access to GLP-1 benefits (lower cost, no needles). Small molecules may have different tissue distribution profiles than peptides, potentially crossing the blood-brain barrier differently (impact on neuro-inflammation needs verification).
    • Translational Gap: As a non-peptide, off-target effects are more likely than with bio-identical peptides. Long-term safety data is absent compared to the 15+ years of data for peptide GLP-1s.
  • Evidence:

3. Anito-cel (Gilead / Arcellx)

  • Target/MOA: BCMA-directed CAR-T Therapy (D-Domain binder).
  • Mechanism: Engineered T-cells that target B-cell Maturation Antigen (BCMA) on myeloma cells. Uses a compact “D-Domain” binder rather than a traditional scFv, potentially reducing immunogenicity.
  • Longevity Potential: None / Negative.
    • Rationale: This is a salvage therapy for terminal cancer. The conditioning chemotherapy (lymphodepletion) required before administration is actively pro-aging (senescence-inducing).
    • Safety: Cytokine Release Syndrome (CRS) and neurotoxicity risks are unacceptable for prevention.
  • Evidence:

4. Brepocitinib (Roivant)

  • Target/MOA: Dual TYK2 / JAK1 Inhibitor.
  • Mechanism: Blocks cytokine signaling (IL-12, IL-23, Type I IFN) involved in autoimmunity.
  • Longevity Potential: Medium (Theoretical) / Low (Practical).
    • Rationale: JAK signaling increases with age and drives the Senescence-Associated Secretory Phenotype (SASP or “inflammaging”). Inhibiting JAK1 can suppress SASP and alleviate frailty in aged mice.
    • Safety Warning: Systemic JAK inhibition in humans is linked to increased risk of infection, shingles, and venous thromboembolism. The therapeutic window for “anti-aging” without immune-compromise is currently unknown.
  • Evidence:

5. Icotrokinra (J&J)

  • Target/MOA: Oral IL-23 Receptor Antagonist Peptide.
  • Mechanism: Selectively blocks IL-23, a cytokine central to the Th17 inflammatory axis (psoriasis, colitis).
  • Longevity Potential: Medium / Emerging Interest.
    • Rationale: Major Update: Recent research identifies the IL-23 receptor (IL-23R) as a circulating biomarker of aging that increases with senescence load. Blocking IL-23 might dampen age-related systemic inflammation more specifically than broad JAK inhibitors.
    • Translational Gap: While IL-23 levels correlate with aging, it is not yet proven that blocking it reverses aging in humans, though senolytics have been shown to reduce IL-23R levels.
  • Evidence:

6. Gedatolisib (Celcuity)

  • Target/MOA: Pan-PI3K / mTOR (mTORC1 & mTORC2) Inhibitor.
  • Mechanism: Blocks the PI3K/AKT/mTOR pathway, which is the master regulator of cell growth and the most validated longevity target (via Rapamycin).
  • Longevity Potential: Low (Too Toxic).
    • Rationale: While mTOR inhibition extends lifespan, pan-PI3K inhibition is highly toxic (severe hyperglycemia, stomatitis, immunosuppression). Gedatolisib hits the right target (mTOR) but with a “sledgehammer” approach intended to kill cancer cells, not tune metabolism. It lacks the specificity of Rapamycin (mTORC1 selective).
  • Evidence:

7. Ulixacaltamide (Praxis)

  • Target/MOA: T-type Calcium Channel Blocker (Cav3.1, Cav3.2, Cav3.3).
  • Mechanism: Modulates neuronal burst firing in the cerebellum-thalamo-cortical circuit to stop tremors.
  • Longevity Potential: Low.
    • Rationale: T-type calcium channels decrease in the heart with age. While blockers are neuroprotective in specific ischemia models, there is no strong evidence suggesting systemic benefits for healthy aging.
  • Evidence:

8. Baxdrostat (AstraZeneca)

  • Target/MOA: Aldosterone Synthase (CYP11B2) Inhibitor.
  • Mechanism: Prevents the production of aldosterone, a hormone that drives hypertension and cardiac fibrosis. Unlike Spironolactone (receptor blocker), this stops the hormone at the source.
  • Longevity Potential: Medium.
    • Rationale: Aldosterone levels promote cardiac fibrosis and vascular aging. Inhibition offers “cleaner” cardiovascular protection than existing mineralocorticoid receptor antagonists (MRAs), potentially without the feminizing side effects of spironolactone. Maintaining low-normal blood pressure is a Tier 1 longevity intervention.
  • Evidence:

9. Camizestrant (AstraZeneca)

  • Target/MOA: Next-Gen SERD (Selective Estrogen Receptor Degrader).
  • Mechanism: Binds to ER-alpha and induces its degradation.
  • Longevity Potential: Negative.
    • Rationale: Estrogen is neuroprotective and bone-protective. Systemic degradation of estrogen receptors in healthy individuals would accelerate osteoporosis and potentially cognitive decline (menopause-like effects).
  • Evidence:

10. Atacicept (Vera Therapeutics)

  • Target/MOA: Dual BAFF / APRIL Inhibitor.
  • Mechanism: Fusion protein (TACI-Fc) that neutralizes B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), reducing pathogenic B-cells and autoantibodies (IgA).
  • Longevity Potential: Low.
    • Rationale: While autoimmunity increases with age, broad B-cell suppression in healthy adults risks compromising humoral immunity against infections.
  • Evidence:
#2

CagriSema results are out today. They are considered OK, not great. I would say it’s a flop. Novo expected 25% weight loss after 26 weeks, but only got 14%. The combination barely matches tirzepatide weight loss, which was 15% after 26 weeks. This keeps tirzepatide on top, with better weight loss, better AE profile, and much better A1c reduction after 52 weeks.

My opinion is that Cagrilintide itself is not a good drug. No one uses it by itself because the side effects at higher dosage are pretty bad, and the weight loss on it alone is mediocre. Eloralintide by Lilly already has a much better profile, an deibust eight loss.

1 Like
#3

Does anyone know how obicetrapib is doing ?